1. Home
  2. RWAY vs ACIU Comparison

RWAY vs ACIU Comparison

Compare RWAY & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Runway Growth Finance Corp.

RWAY

Runway Growth Finance Corp.

HOLD

Current Price

$6.47

Market Cap

274.5M

Sector

N/A

ML Signal

HOLD

Logo AC Immune SA

ACIU

AC Immune SA

HOLD

Current Price

$2.42

Market Cap

247.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RWAY
ACIU
Founded
2015
2003
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
274.5M
247.6M
IPO Year
2015
2015

Fundamental Metrics

Financial Performance
Metric
RWAY
ACIU
Price
$6.47
$2.42
Analyst Decision
Buy
Strong Buy
Analyst Count
8
4
Target Price
$8.04
★ $8.57
AVG Volume (30 Days)
★ 268.1K
182.8K
Earning Date
11-05-2026
11-03-2026
Dividend Yield
★ 20.80%
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
$3.42
$422.39
Revenue Next Year
$5.12
$377.85
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.19
$2.10
52 Week High
$10.20
$4.00

Technical Indicators

Market Signals
Indicator
RWAY
ACIU
Relative Strength Index (RSI) 50.22 42.07
Support Level $6.32 $2.40
Resistance Level $6.57 $2.68
Average True Range (ATR) 0.14 0.09
MACD 0.00 -0.00
Stochastic Oscillator 78.12 18.92

Price Performance

Historical Comparison
RWAY
ACIU

About RWAY Runway Growth Finance Corp.

Runway Growth Finance Corp is a specialty finance company focused on providing senior secured loans to high-growth-potential companies in technology, life sciences, healthcare information and services, business services, select consumer services and products, and other high-growth industries. The company has Investments in the United States, Germany, and UK, Canada, Netherlands, with the majority of its portfolio invested in the United States. The company's investment objective is to maximize its total return to its stockholders through current income on its loan portfolio, and secondarily through capital gain on its warrants and other equity positions.

About ACIU AC Immune SA

AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.

Share on Social Networks: